Scrip Intelligence, a leading source of news and strategic analysis for the global pharmaceutical industry, publish article about Isofol Medical
John Davis, journalist and editor for more than 30 years, of Scrip Intelligence recently interviewed Anders Rabbe, CEO of Isofol Medical AB, regarding the fundamental strategy behind the company’s recent IPO and important lessons learned from that process.
The article has been made available and can be read via the link below:
https://isofolmedical.com/wp-content/uploads/2017/07/ExecutiveInterviewScrip.pdf
Scrip intelligence – Pharmaceutical and biotech intelligence division of Informa
Scrip intelligence is a leading source of news and strategic analysis for the global pharmaceutical industry, providing customers with timely business-critical market and competitor intelligence. SCRIP has over 14,000 registered users consisting of mid-to-C-Level managers and executives working across all disciplines in pharmaceutical and biotech companies, worldwide. The service attracts 35,000 unique web visitors every month with potential partnering intentions.
For more information, please contact:
Anders Rabbe, CEO, Isofol Medical AB
Email: anders.rabbe@isofolmedical.com
Phone: +46 (0)707 646 500
About Modufolin®
Modufolin® (active ingredient [6R]-5,10-methylenetetrahydrofolate), is a novel folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. As Modufolin® does not require metabolic activation to exert it’s effect, Modufolin® is suitable for all patients irrespective of their capacity to activate folates. Modufolin® is currently being evaluated in a clinical Phase II study.
About Isofol Medical AB
Isofol Medical AB is a clinical stage oncology company developing Modufolin® as a first-line treatment of metastatic colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma. Through a worldwide exclusive license agreement, Isofol Medical holds the rights to commercialise Modufolin® with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the NASDAQ First North Premier. Certified Adviser is FNCA Sweden AB
